 | Up a level |
2021
Fuerstenau, Moritz, Giza, Adam, Stumpf, Thomas, Robrecht, Sandra, Maurer, Christian, Linde, Hartmut, Jacobasch, Lutz, Doerfel, Steffen, Aldaoud, Ali, von Tresckow, Julia, Koenigsmann, Michael, Gaska, Tobias, Kaiser, Ulrich, Harich, Hanns-Detlev, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Fink, Anna-Maria (2021). Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia. Am. J. Hematol., 96 (12). S. E457 - 4. HOBOKEN: WILEY. ISSN 1096-8652
Rautenberg, Christina, Stoelzel, Friedrich, Roellig, Christoph, Stelljes, Matthias, Gaidzik, Verena, Lauseker, Michael, Kriege, Oliver, Verbeek, Mareike, Unglaub, Julia Marie, Thol, Felicitas, Krause, Stefan W., Haenel, Mathias, Neuerburg, Charlotte, Vucinic, Vladan, Jehn, Christian-Friedrich, Severmann, Julia, Wass, Maxi, Fransecky, Lars, Chemnitz, Jens, Holtick, Udo, Schaefer-Eckart, Kerstin, Schroeder, Josephine, Kraus, Sabrina, Krueger, William, Kaiser, Ulrich, Scholl, Sebastian, Koch, Kathrin, Henning, Lea, Kobbe, Guido, Haas, Rainer, Alakel, Nael, Roehnert, Maximilian-Alexander, Sockel, Katja, Hanoun, Maher, Platzbecker, Uwe, Holderried, Tobias A. W., Morgner, Anke, Heuser, Michael, Sauer, Tim, Goetze, Katharina S., Wagner-Drouet, Eva, Doehner, Konstanze, Doehner, Hartmut, Schliemann, Christoph, Schetelig, Johannes, Bornhaeuser, Martin, Germing, Ulrich, Schroeder, Thomas and Middeke, Jan Moritz (2021). Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood Cancer J., 11 (10). LONDON: SPRINGERNATURE. ISSN 2044-5385
2014
Hohloch, Karin, Zwick, Carsten, Ziepert, Marita, Hasenclever, Dirk, Kaiser, Ulrich, Engert, Andreas, Hoeffkes, Heinz-Gert, Kroschinsky, Frank, Mesters, Rolf, Feller, Andreas C., Loeffler, Markus, Truemper, Lorenz and Pfreundschuh, Michael (2014). Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL. SpringerPlus, 3. CHAM: SPRINGER INTERNATIONAL PUBLISHING AG. ISSN 2193-1801